Navigation Links
Nektar Presents Data Demonstrating Favorable Oral Bioavailability and Drug-Drug Interaction Profile for NKTR-118
Date:9/13/2009

SAN ANTONIO and SAN CARLOS, Calif., Sept. 13 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) presented clinical study data today demonstrating that the oral tablet formulation of NKTR-118 has favorable systemic bioavailability and a low risk for mediating significant drug-drug interactions. NKTR-118, an oral peripherally-acting opioid antagonist, is in clinical development for the treatment of opioid-induced constipation. These findings were presented today at the 38th Annual American College of Clinical Pharmacology (ACCP) Meeting in San Antonio, Texas.

Oral NKTR-118 combines Nektar's advanced small molecule polymer conjugate technology platform with naloxol, a derivative of the opioid-antagonist drug, naloxone. Nektar's proprietary advanced polymer conjugate technology increases the bioavailability and half-life of naloxol, enabling NKTR-118 to act selectively in the periphery while preserving centrally-mediated opioid analgesic clinical benefits.

"The data reported today, in combination with our strong Phase 2 clinical results, support advancing the oral tablet formulation of NKTR-118 into pivotal Phase 3 studies. NKTR-118 is an excellent example of how our novel advanced polymer conjugate platform improves oral bioavailability and enables preferential distribution of a drug within the body," said Lorianne Masuoka, M.D., Chief Medical Officer of Nektar. "By significantly improving the pharmacological activity of small molecule drugs, we are building an impressive portfolio of innovative treatments for diseases with high unmet needs."

A human pharmacokinetic study conducted in 20 healthy subjects demonstrated the comparative bioavailability of NKTR-118 in tablets and solution, confirming the drug's rapid absorption prof
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
2. Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction
3. Nektar Terminates All Negotiations With Potential Partners for Inhaled Insulin; Increased Number of Lung Cancer Cases Observed in Ongoing Clinical Studies of Inhaled Insulin Patients
4. Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings
5. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
6. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
7. Nektar Announces Positive Results from Phase 2 Study of Oral NKTR-118 in Patients with Opioid-Induced Constipation (OIC)
8. Nektar Therapeutics Reports Second Quarter 2009 Financial Results
9. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
10. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
11. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)...  Membership in Medicare Supplement plans continued to ... Strategy report released by Mark Farrah Associates (MFA).  ... Med Supp plans, covered approximately 11.2 million seniors ... from 2013. Between 2013 and 2014, enrollment in ... Though UnitedHealth was the segment growth leader, many ...
(Date:5/6/2015)... , May 05, 2015 Research and Markets ... addition of the "Chromatography (Instruments and Reagents) ... to their offering. Chromatography is an ... the component of a complex mixture by differential ... decades the scientists have considered chromatography as an ...
(Date:5/6/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/4fgrnh/asiapacific ) ... Internal Trauma Fixation Devices Market by Type & ... report to their offering. The ... to grow at a CAGR of 6.7% from ... rising incidences of road accidents, increasing aging population, ...
Breaking Medicine Technology:Continued Growth in Med Supp Market for 2014 according to Mark Farrah Associates 2Global Chromatography (Instruments and Reagents) Market 2015 - Forecasts to 2019 2Asia-Pacific Internal Trauma Fixation Devices (Internal Trauma Fixation Plates, Screws, Rod Wires & Pins, Fusion Nails) Market 2015 2
... , , ATLANTA , Feb. ... for Economic and Clinical Health (HITECH) Act, Elekta has expanded its ... advantage of the financial incentives available from the federal government. These ... certified EMR systems who are able to demonstrate meaningful use. , ...
... , PITTSBURGH , Feb. 4 Mylan ... by Pfizer in connection with the filing of an Abbreviated New ... for Amlodipine Besylate and Atorvastatin Calcium Tablets 2.5/10 mg, 2.5/20 mg, ... mg, 10/20 mg, 10/40 and 10/80 mg. This product is the ...
Cached Medicine Technology:Elekta Expands Consultative Services Program to Help MOSAIQ Customers Demonstrate Meaningful Use Guidelines 2Elekta Expands Consultative Services Program to Help MOSAIQ Customers Demonstrate Meaningful Use Guidelines 3Mylan Confirms First-to-File Patent Challenge Relating to Caduet(R) 2
(Date:5/7/2015)... May 07, 2015 When people think about ... consideration to their roofs than their basements. However, heavy rain ... in crawlspaces and basements. While flooding is an obvious problem ... crawlspaces and unfinished areas dry to avoid a musty ... Damp Basement, Even small amounts of water can cause foundation ...
(Date:5/7/2015)... 07, 2015 Five CHI Health ... Health Bergan Mercy, CHI Health Immanuel and CHI ... in Papillion, Neb.; and CHI Health Mercy in ... achieving high-quality standards of care by the Accreditation ... to best practices in cardiovascular care. The five ...
(Date:5/6/2015)... 2015 Device Patent Law Changes:, Six Key ... a.m. – 12:30 p.m. EDT, http://www.fdanews.com/DevicePatentLaw , Every ... lawsuits and claims that waste their time. , It ... could be prevented if devicemakers better understand the trouble spots ... and revisions to patent laws from all around the world. ...
(Date:5/6/2015)... the exclusive hospital of the Tampa Bay Buccaneers, Florida Hospital ... James Stadium for all the “Bucs Babies” celebrating their first ... the “Bucs Babies” program last year. , “It is ... those born at the Florida Hospitals here in our community, ... enjoyed my time participating in the festivities, interacting with the ...
(Date:5/6/2015)... 06, 2015 On April 27, 2015, ... Plastic Surgery ,” compiled quotes about cosmetic surgery from ... pop singer Iggy Azalea, and Gwyneth Paltrow. For the ... having plastic surgery themselves; only a couple ... its expectations of youth and beauty. (see: goo.gl/wSomih) , ...
Breaking Medicine News(10 mins):Health News:Spring Storms Bring Musty Smell Inside 2Health News:Spring Storms Bring Musty Smell Inside 3Health News:Five CHI Health Facilities in Nebraska, Iowa Recognized for High-Quality Care by Accreditation for Cardiovascular Excellence 2Health News:Five CHI Health Facilities in Nebraska, Iowa Recognized for High-Quality Care by Accreditation for Cardiovascular Excellence 3Health News:FDAnews Announces — Device Patent Law Changes: Six Key Areas of Concern Webinar, May 27, 2015 2Health News:FDAnews Announces — Device Patent Law Changes: Six Key Areas of Concern Webinar, May 27, 2015 3Health News:Florida Hospital and the Tampa Bay Buccaneers Celebrate “Bucs Babies” Who are Turning One this Month with a Party on the Pirate Ship 2Health News:Florida Hospital and the Tampa Bay Buccaneers Celebrate “Bucs Babies” Who are Turning One this Month with a Party on the Pirate Ship 3Health News:Plastic Surgery: Sixteen Celebrities Offer their Opinion about Going Under the Knife 2
... 1 Skin damage. If,you are over 40, your skin ... as a smoker (lip lines), those long, lazy sun-worshipping summers,(dry, ... a little more of Mom and Pop in the mirror ... seeing is normal skin aging, but most of it is,likely ...
... to Fujifilm,s ... broad DR product line, STAMFORD, Conn., ... the FDA 510(k) clearance of its newest Fuji DR,(FDR) system, the ... system that can perform a variety of exams with,only one detector. ...
... BOULDER, Colo., Feb. 29 The National Patient,Safety ... Road Taken,Together," stresses the importance of improving healthcare ... and communities., Supporting National Patient Safety Awareness ... (Amex: ECI ) urges communities to,actively partner ...
... the odds? Today, at,Gulf Coast Medical Center in Panama City, ... Year babies. That news may not make,headlines, but consider the ... Joe, Florida and their husbands work together at the,Port St. ... were together helping put out a hotel fire when they ...
... how certain proteins, including,Hax1, work and how ... Tenn., Feb. 29 Investigators at St.,Jude Children,s ... that,protects certain cells from undergoing apoptosis, also known ... apoptosis is important to,researchers seeking ways to control ...
... Plans to Separate Medical ... Funeral Services Businesses, BATESVILLE, Ind., Feb. 29 Hillenbrand,Industries, ... it has,commenced a cash tender offer to purchase any and ... No. 431573AD6), of which $250,million in aggregate principal amount was ...
Cached Medicine News:Health News:The DOT CO2 Fractional: The Next Step in Laser Skin Resurfacing 2Health News:The DOT CO2 Fractional: The Next Step in Laser Skin Resurfacing 3Health News:The DOT CO2 Fractional: The Next Step in Laser Skin Resurfacing 4Health News:Fujifilm Receives FDA Approval for Unity SpeedSuite(TM) 2Health News:Fujifilm Receives FDA Approval for Unity SpeedSuite(TM) 3Health News:Encision Supports National Patient Safety Awareness Week 2Health News:St. Jude Researchers Find Key Step in Programmed Cell Death 2Health News:St. Jude Researchers Find Key Step in Programmed Cell Death 3Health News:Hillenbrand Industries, Inc. Announces 'Any and All' Cash Tender Offer for Its 4.50 percent Senior Notes Due 2009 2Health News:Hillenbrand Industries, Inc. Announces 'Any and All' Cash Tender Offer for Its 4.50 percent Senior Notes Due 2009 3Health News:Hillenbrand Industries, Inc. Announces 'Any and All' Cash Tender Offer for Its 4.50 percent Senior Notes Due 2009 4Health News:Hillenbrand Industries, Inc. Announces 'Any and All' Cash Tender Offer for Its 4.50 percent Senior Notes Due 2009 5
Curved shafts with 2 mm angled platform. Wide serrated handle with dull finish....
Straight shafts with fine tips and dull finish. Insulated stop with tip gap set at 0.3 mm. Smooth handle....
Straight shafts with micro tips and sandblast finish. Insulated smooth handle....
Straight shafts with rounded tips. Smooth handle with dull finish....
Medicine Products: